Corrective Phases R...
Health Care: Drugs
Corcept Therapeutics Inc. (CORT: NASDAQ)
$4.08 -0.01 | -0.24%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 4.08 |
| 52 Week High | 4.90 |
| 52 Week Low | 2.50 |
| Avg. Daily Vol. (Mil) | 0.32 |
| Beta (3 year) | 1.21 |
| Share Related Items | |
| Mkt Cap (Mil) | 361.60 |
| Shares Out (Mil) | 88.63 |
| Float (Mil) | 53.71 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 11.00 |
| Current Ratio | 12.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 9.20 |
| Price/Cash Flow | -10.00 |
| Per Share Data | |
| Earnings | -0.44 |
| Sales | 0.00 |
| Book Value | 0.44 |
| Cash Flow | -0.41 |
| Business Summary | |
|---|---|
| Corcept Therapeutics Incorporated is pharmaceutical company, engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. | |
| General Information | |
| 149 Commonwealth Drive
Menlo Park, CA 94025 |
|
| www.corcept.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 31 | |
| CEO: Joseph K. Belanoff,M.D. | |
| Short Interest | |
| Current Month (Mil) | 4.48 |
| Previous Month (Mil) | 4.10 |
| Short Interest Ratio (Days) | 25.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -84.60 |
| Return on Investments | -92.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CORT
- Portfolio NameUser Type
- Userwayne120
- Userespwes06 Portfolio 1
- ContributorStocks Under-$10 Moving Hig...
- ContributorTop 10 'Buy'-Rated Stocks U...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- Userrubylu02
- UserBarron's Insider Purchases ...
- Usermicahw29 Portfolio 1
- Userrktjky Portfolio 1
Latest CORT Headlines from TheStreet
- Corcept Has Upside Following Drug Approval 02.21.12 | 12:02 pm
- 7 Stocks Under $10 Moving Higher 02.16.12 | 02:02 pm
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Biotech Stock Mailbag: Corcept Therapeutics, Reader Retorts 02.10.12 | 07:02 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 27 Hot Drugs Facing FDA Approval in 2012 12.19.11 | 10:12 am
- Biotech Calendar: Key Dates for March 03.02.11 | 08:03 am
- Danver Bancorp, Dean Foods: Small-Cap Winners 01.21.11 | 01:01 pm
- Biotech Calendar: Key Dates for December 11.30.10 | 07:11 am
- Novartis Cushing's Drug Passes Late-Stage Test 09.22.10 | 07:09 am
Press Releases for CORT
Partner Headlines for CORT
- Company News for February 22, 2012 - Corporate Summary - Zacks 02.22.12 | 10:02 am
- UPDATE: Stifel Nicolaus Increases Target to $9 on Concept Therepeutics - Benzinga 02.21.12 | 09:02 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- Upcoming PDUFA Dates for Sub-$5 Stocks - Seeking Alpha 07.05.11 | 09:07 am
- 14 Oversold Stocks With Bearish Options - Seeking Alpha 07.01.11 | 08:07 am
- 10 Undervalued Biotech Stocks With Insider Buying - Seeking Alpha 06.23.11 | 06:06 am
- 7 Small-Cap Biotechs With Bullish Insider Buying in 2011 - Seeking Alpha 06.12.11 | 05:06 am
- Low Beta Ideas: 22 High Growth, Low Beta Stocks Being Snapped Up by Mutual Funds - Seeking Alpha 06.09.11 | 09:06 am
- Upgrades, Downgrades and Initiations for Monday - Seeking Alpha 06.06.11 | 09:06 am
- UPDATE 2-Corcept hormone disorder drug meets main trial goal - Reuters 12.22.10 | 11:12 am
